Pfizer expands into gene editing with Beam research deal

Bio Pharma Dive

Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases

Vertex aligns with another CRISPR gene editing startup

Bio Pharma Dive

A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna, teaming with a startup, wades further into gene editing

Bio Pharma Dive

The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions

Beam, Apellis partner in deal to expand gene editing's reach

Bio Pharma Dive

The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing

Gene editing biotech Verve to raise $267M in large IPO

Bio Pharma Dive

Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year

Gene editing startup Metagenomi raises $175M to advance research pipeline

Bio Pharma Dive

The biotech raised the Series B round during "probably one of the worst biotech markets" emerging drugmakers have faced in some time, a Metagenomi executive told BioPharma Dive

Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

Bio Pharma Dive

Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research

Lilly dives into gene editing

Bio Pharma Dive

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy

Gene editing: beyond the hype

Pharma Phorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Zinc fingers are the most common control gene in the body,” Macrae explains. “We Gene therapy can ultimately only take you into the liver,” he explains.

AbbVie exploring how CRISPR gene editing can improve cell therapies

Bio Pharma Dive

Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system

Gene-editing used to create single sex mice litters

Scienmag

After long wait, Editas reveals first data for CRISPR gene editing treatment

Bio Pharma Dive

Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions

Bayer and Mammoth Biosciences collaborate on novel gene editing tech

BioPharma Reporter

have announced a strategic collaboration and option agreement for the use of Mammothâs CRISPR systems to develop in vivo gene-editing therapies. Bayer AG and Mammoth Biosciences, Inc.,

Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work

Bio Pharma Dive

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers

JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets

Bio Pharma Dive

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking

CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder

Bio Pharma Dive

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Bio Pharma Dive

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others

A CRISPR gene editing treatment continues to show promise for two blood diseases

Bio Pharma Dive

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Bio Pharma Dive

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

BioTech 365

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology Agreement strengthens Bayer’s new cell and gene therapy platform further Supports Mammoth’s vision of unlocking the full potential … Continue reading → Business Wire

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research

Gene-edited cell replacement therapy for diabetes set to enter the clinic

BioPharma Reporter

have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). CRISPR Therapeutics and ViaCyte, Inc.

Gene-editing discovery yields high promise for wheat fertility in a changing climate

Scienmag

Credit: John Innes Centre A gene which has profound effects on the production of seeds has been identified by researchers from the John Innes Centre.

Medicine of the Future Happening Today - Seelos Sees Promise for In Vivo Gene Editing

BioSpace

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures

Moderna Moves Into Gene Editing Space with Metagenomi R&D Collab

BioSpace

The partnership will leverage Metagenomi’s novel gene editing technology and Moderna’s mRNA platform, in addition to its lipid nanoparticle delivery technologies

Will Intellia Make Gene Editing History Saturday?

BioSpace

In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body

Gene Editing Breakthroughs Accelerate Heart, Stroke Research

BioSpace

?Gene therapy research delivers breakthroughs this week with a CRISPR-edited droplet that could lead to a cure for heart disease and the possibility of turning glial brain cells into neurons

Beam, Verve stockpile cash as investors bank on gene editing progress

Bio Pharma Dive

Beam expects to receive $260 million through a private stock placement, while Verve raised $94 million to support initial studies of its heart disease treatment

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

Pharma Phorum

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that could be worth up to $1.2

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical

BioTech 365

GenEdit Uncloaks to Solve Gene Editing “Delivery Problem”

BioSpace

Kunwoo Lee has uncloaked his solution to the gene-editing “delivery problem” with $26 million in Series A funds for his company, GenEdit

#news #biotech Scientists produce new antibiotics by gene editing

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists produce new antibiotics by gene editing.Scientists have discovered a new route to produce complex antibiotics exploiting gene editing to re-program pathways to future medicines urgently required … Continue reading → #news

#news #biotech UK clears the way for gene-edited crops

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: UK clears the way for gene-edited crops. from European Biotechnology – first and foremost in European biotech [link].

#news #biotech New gene-edited barley that could improve beer

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: New gene-edited barley that could improve beer.After a spell of unexpected rain, before the harvest season, a farmer may be faced with the unpredictable problem of untimely … Continue reading → #news

Gene-editing produces tenfold increase in superbug slaying antibiotics

Scienmag

Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. Credit: Dr Dino J.

#news #biotech JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks.JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucks … Continue reading → #news

#news #biotech Gene-editing used to create single sex mice litters

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Gene-editing used to create single sex mice litters.Scientists at the Francis Crick Institute, in collaboration with University of Kent, have used gene editing technology to create female-only … Continue reading → #news

A Pivotal Moment for CRISPR in the Gene Editing Journey

BioSpace

With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

BioTech 365

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China Cytovia Commits to Additional Milestones and Equity grant AVENTURA, Fla.

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

BioTech 365

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy … Continue reading → Business Wire

#news #biotech Moderna finally cracks into gene editing with Metagenomi pact thanks to ‘irresistible’ data

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Moderna finally cracks into gene editing with Metagenomi pact thanks to ‘irresistible’ data.Moderna finally cracks into gene editing with Metagenomi pact thanks to ‘irresistible’ data aarmstrong Mon, … Continue reading → #news

Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference

BioTech 365

Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART … Continue reading → Business Wire

Researchers recommend more transparency for gene-edited crops

Scienmag

Media contacts: Jennifer Kuzma, jkuzma@ncsu.edu Khara Grieger, kdgriege@ncsu.edu Mick Kulikowski, News Services, 919.218.5937 or mick_kulikowski@ncsu.edu Researchers at North Carolina State University call for a coalition of biotech industry, government and non-government organizations, trade organizations, and academic experts to work together to provide basic information about gene-edited crops to lift the veil on how plants or […].